Latest Information Update: 23 Nov 2016
At a glance
- Originator Theravance
- Class Urologics
- Mechanism of Action Muscarinic M2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Overactive bladder
Most Recent Events
- 12 May 2006 Discontinued - Phase-I for Overactive bladder in USA (unspecified route)
- 15 Apr 2004 Phase-I clinical trials in Overactive bladder in USA (unspecified route)